CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...
Last year’s federal agency layoffs, grant discontinuations, and university funding cuts led to numerous warnings of the disastrous impact on U.S. science research. Gretchen Goldman, PhD, from the ...
CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results